Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT ID: NCT00034801
Last Updated: 2006-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
378 participants
INTERVENTIONAL
2001-09-30
2003-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
olanzapine
ziprasidone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Female subjects of childbearing potential must be using a medically accepted means of contraception
* Each subject must have a level of understanding sufficient to perform all tests and examinations required by the protocol
* Subjects must be considered reliable
Exclusion Criteria
* Female subjects who are either pregnant or nursing
* Uncorrected hypothyroidism or hyperthyroidism
* Narrow-angle glaucoma
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tuscaloosa, Alabama, United States
Little Rock, Arkansas, United States
Anaheim, California, United States
Chula Vista, California, United States
Lafayette, California, United States
Long Beach, California, United States
Orange, California, United States
Poway, California, United States
Rosemeade, California, United States
San Diego, California, United States
Denver, Colorado, United States
New Britain, Connecticut, United States
Winter Park, Florida, United States
Augusta, Georgia, United States
Prairie Village, Kansas, United States
Gaithersburg, Maryland, United States
Mount Pleasant, Michigan, United States
St Louis, Missouri, United States
Lincoln, Nebraska, United States
Clementon, New Jersey, United States
Buffalo, New York, United States
New York, New York, United States
Staten Island, New York, United States
Charlotte, North Carolina, United States
Philadelphia, Pennsylvania, United States
Sioux Falls, South Dakota, United States
Austin, Texas, United States
El Paso, Texas, United States
Houston, Texas, United States
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
F1D-US-HGJU
Identifier Type: -
Identifier Source: secondary_id
5529
Identifier Type: -
Identifier Source: org_study_id